Back to home » Top Stories » CROI 2011
CROI 2011
CROI 2011 18th Conference on Retroviruses and Opportunistic Infections
Hynes Convention Center
Boston, MA
February 27 - March 2, 2011

emailprint

CD4s, Viral Load Not Enough to Predict Survival During HIV Treatment

March 8, 2011

As AIDS-related illnesses decline and non-AIDS complications become increasingly more common in the modern antiretroviral (ARV) therapy era, looking at six blood markers—not just CD4 cell counts and viral load—will be necessary to make accurate survival predictions. This is the conclusion of a study conducted by researchers at Yale and Harvard universities and reported on Monday, February 28, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

As people living with HIV continue to respond favorably to ARV treatment, explained researcher Amy Justice, MD, PhD, of Yale and the Veterans Administration (VA) Connecticut Healthcare System, there is increased interest in factors associated with aging, beyond standard CD4 count and viral load measurements, that may influence survival rates.

The Veterans Aging Cohort Study (VACS) Index, composed of routine lab measurements of organ system injury, has been shown to predict death from any cause more accurately than an index restricted to CD4s and viral load. Studies thus far testing the VACS Index, however, have been limited to veterans. What has not yet been tested is whether the VACS Index is applicable to the average population: non-veterans receiving ARV treatment.

In addition to viral load, CD4 cell counts and age, the VACS Index includes markers for anemia (hemoglobin measurements), kidney injury (estimated glomerular filtration rate, or eGFR), liver injury (blood labs indicative of liver fibrosis, or FIB-4) and hepatitis C infection status.

To conduct its analysis, Justice’s group turned to data involving 5,980 people living with HIV participating in either the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) or the Canadian Cohort Collaboration (CANOC). To establish a baseline, the researchers randomly selected a CD4 count for each patient—at least a year after they’d been on ARV treatment—along with other VACS Index blood tests conducted around the same time as the CD4 cell measurement. They then looked at the deaths, from any causes, among the nearly 6,000 patients during the next five years.

According to Justice’s report, the VACS Index predicted five-year mortality—from any cause—substantially better than an index restricted to CD4 cell count, viral load and age in the two cohorts, which she said represented North Americans on ARV therapy with varying periods of HIV treatment experience.

“The variables included in the VACS Index are recommended for routine monitoring by current guidelines,” Justice and her colleagues concluded. “Because the VACS Index both accurately predicts mortality and indicates specific organ systems at risk, it may be a useful tool with which to monitor treatment response and assess prognosis among those on [ARV therapy].”

Search: Veterans Administration, VACS Index, survival, viral load, HIV-RNA, CD4 count, FIB-4, eGFR, age, hemoglobin, anemia, kidney, liver, Justice, Yale, Harvard, CROI

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (3 total)

More from CROI 2011

HIV/AIDS Complications

March 11, 2011
Hep B Ups Death Risk Compared With Hep C, but Tenofovir Seems Protective
March 8, 2011
CD4s, Viral Load Not Enough to Predict Survival During HIV Treatment
HIV Non-Nuke Rilpivirine Less Likely Than Sustiva to Cause Vitamin D Drops
The Effect of Antiretroviral Treatment on Cancer Risk
March 7, 2011
Aging and HIV: Older HIV-Positive Men Are Frailer Than Similar HIV-Negative Men
March 4, 2011
Bone Loss During HIV Treatment: A Possible Side Effect of CD4 Cell Recovery
Non-AIDS-Related Cancers Are Now the Leading Cause of Death in People With HIV
March 3, 2011
Study Says HIV and Inflammation, Not ARVs, Predict Cardiovascular Risk
March 2, 2011
Muscle Loss, Fat Gain Associated With Increased Risk of Death
March 1, 2011
Previous Syphilis Infection Might Cause Poorer Brain Function for People With HIV
FDA Analysis: No Increased Heart Attack Risk While Using Abacavir

HIV Transmission and Prevention

March 10, 2011
HIV Test and Treat: Challenges to Overcome
March 7, 2011
Test and Treat Success Stories: Community Viral Load Predicts HIV Transmission Declines
March 4, 2011
U.S. Women Prefer a Pill Over a Vaginal Gel for Prevention
March 1, 2011
First Rectal Gel Studies Show Real Promise

Starting and Switching Treatment

March 9, 2011
Adolescents Have a Hard Time Doing Well in Adult HIV Care
March 8, 2011
Are People Experiencing More Rapid HIV Disease Progression Now?
March 7, 2011
After 2 Years, Drug Regimen Works Well Among Treatment-Experienced
March 3, 2011
Isentress Has Long-Term HIV Efficacy and Safety, but Is Best Taken Twice Daily
March 1, 2011
Risk of Virologic Failure 40 Percent Higher Among Blacks vs. Whites

Experimental HIV Drugs

March 9, 2011
Malaria Drug Plaquenil Calms Immune Activation
March 3, 2011
New Version of Tenofovir Is Much More Potent and Hopefully Safer
March 2, 2011
ViiV Integrase Inhibitor Dolutegravir Is Better Twice-Daily for Treatment-Experienced People
March 1, 2011
Encouraging Results for BMS’s Oral HIV Attachment Inhibitor
February 28, 2011
CCR5 Gene Therapy Shows HIV Treatment Potential


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.